Performance metrics and trade details for INSM breakout.
On June 10th (pre-market), Insmed (INSM) announced positive results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP) as a once-daily therapy for patients with pulmonary arterial hypertension. The stock reacted sharply to the news, gapping up approximately 25%.
Leading up to this catalyst, INSM had been trading sideways for about a year, forming a flat Darvas box base—indicating a period of consolidation and accumulation. The strong clinical data served as a breakout trigger from this base, marking a potential shift in trend driven by a significant product development milestone.
